Grant: Doctoral Research Award-PA: HIV/AIDS Research (SHOPP)-Basic Science
University of Toronto
$52,500.00
Investigating the role of the glucocorticoid-induced tumour necrosis factor receptor in chronic viral infection and evaluating its efficacy as a target for therapy
EF 2012-13
Résumé
During an acute viral infection, such as influenza virus, cells of the immune system are able to detect the presence of the pathogen, launch a response against it, and finally, eliminate it from the host. However, when the virus persists, such as with human immunodeficiency virus (HIV) infection, the immune system is forced to turn down the immune response and "truce" with the pathogen, otherwise chronic activation of the immune system would result in destruction of not only infected cells, but would also cause collateral damage to uninfected cells (termed "immunopathology"). The immune suppressive mechanisms that turn the cells "OFF" to prevent immunopathology are also therefore responsible for increased viral persistence. Although antiretroviral drugs are quite good at limiting HIV infection, they do not completely eliminate virus - and are therefore not a cure. As such, there exists a need for the development of novel therapies to complement drug treatment to eliminate the infection. What we propose is targeting a molecule on these "OFF" state immune cells to turn them back "ON" so that function is restored in hopes of eliminating the virus. Bearing in mind that since the immune system has turned "OFF" these cells to prevent collateral damage, turning it back "ON" is not without risk. However, to date our early studies have shown no negative side effects, but instead have dramatically improved the control of chronic infection in mouse models. We now must: first, gain a complete understanding the mechanism(s) of this therapy to properly evaluate safety and efficacy; and second, aim to translate this knowledge into a therapy for chronic viral infection in human (HIV) settings.
Programme
Doctoral Research Award-PA: HIV/AIDS Research (SHOPP)-Basic Science
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
277460
Name
Clouthier Derek L
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association for HIV Research (Ottawa)
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the role of the glucocorticoid-induced tumour necrosis factor receptor in chronic viral infection and evaluating its efficacy as a target for therapy
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$52,500
Cihrequipment2
$0
Programname2
Doctoral Research Award-PA: HIV/AIDS Research (SHOPP)-Basic Science
Keyworddelim
Agonistic Antibody Therapy; Cd8 T Cells; Chronic Viral Infection; Co-Stimulatory Molecules; Gitr; Immune Dysregulation; Lcmv; Regulatory T Cells; Tnfr Superfamily; Trafs
Abstract
During an acute viral infection, such as influenza virus, cells of the immune system are able to detect the presence of the pathogen, launch a response against it, and finally, eliminate it from the host. However, when the virus persists, such as with human immunodeficiency virus (HIV) infection, the immune system is forced to turn down the immune response and "truce" with the pathogen, otherwise chronic activation of the immune system would result in destruction of not only infected cells, but would also cause collateral damage to uninfected cells (termed "immunopathology"). The immune suppressive mechanisms that turn the cells "OFF" to prevent immunopathology are also therefore responsible for increased viral persistence. Although antiretroviral drugs are quite good at limiting HIV infection, they do not completely eliminate virus - and are therefore not a cure. As such, there exists a need for the development of novel therapies to complement drug treatment to eliminate the infection. What we propose is targeting a molecule on these "OFF" state immune cells to turn them back "ON" so that function is restored in hopes of eliminating the virus. Bearing in mind that since the immune system has turned "OFF" these cells to prevent collateral damage, turning it back "ON" is not without risk. However, to date our early studies have shown no negative side effects, but instead have dramatically improved the control of chronic infection in mouse models. We now must: first, gain a complete understanding the mechanism(s) of this therapy to properly evaluate safety and efficacy; and second, aim to translate this knowledge into a therapy for chronic viral infection in human (HIV) settings.
Competitiondate
201210
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Clouthier, Derek L
Approvedterm
3 ans 0 mois
Cihrcontribution2
SPIR~ $52,500~ $0~